Knowledge, Attitude and Practice about Glucagon-like Peptide-1 Receptor Agonist Among the Physicians of Prince Mohammed bin Abdulaziz Hospital & Primary Health Care, National Guard, Saudi Arabia

Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a newly approved medication in the management of Diabetes Mellitus. GLP-1RA has potential adverse effects and risks such as gastrointestinal symptoms, pancreatitis, and thyroid cell neoplasia, respectively. A cross-sectional study, through a validated questionnaire with fixed answers, was utilized to assess the physician’s response regarding GLP-1RA. Participants were Saudi females, younger than 35 years. Physicians with variable educational degrees were included. In regard to prescription authority, it was limited to only around 25.5% of the treating physicians. Knowledge items were scored correctly by 77.2% of participants. And around half of the group 51.6% showed a positive attitude toward GLP-1RA, reflected as strongly agree and agree in the questionnaire. And only 55.2% of participants showed good practice in terms of utilization of GLP-1RA. These findings suggest that continuous professional development and well-organized training programs are crucial to bridge knowledge gaps and refine practice patterns. Keywords: Knowledge, Attitude, Practice, Glucagon-like peptide-1 receptor agonist, Physicians